The effects of perhexiline on the rat coronary vasculature

European Journal of Pharmacology

Volumn 370, Issue 3, 1999, Pages 263-270

  Kennedy, Jennifer A ^a   Mohan, Puneet ^a   Pelle, Maria A ^a   Wade, Steven R ^a   Horowitz, John D ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Coronary circulation; EDHF (endothelium derived hyperpolarising factor); Endothelium; Nitric oxide (NO); Perhexiline

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; APAMIN; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GLIBENCLAMIDE; INDOMETACIN; NITRIC OXIDE; PERHEXILINE; PROADIFEN; TETRABUTYLAMMONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; HUMAN TISSUE; INOTROPISM; ISOLATED HEART; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL FACTORS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EPOPROSTENOL; HEART VENTRICLES; MALE; MUSCLE, SMOOTH; NITRIC OXIDE; NITROPRUSSIDE; OCTOXYNOL; PERFUSION; PERHEXILINE; RATS; VASODILATOR AGENTS;

EID: 0032939997     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00106-5     Document Type: Article

References (30)

1. Barry W.H., Horowitz J.D., Smith T.W. Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells. Br. J. Pharmacol. 85:1985;51-59.
2. Becker L.C. Conditions for vasodilator-induced coronary steal in experimental myocardial ischaemia. Circulation. 57:1978;1103-1110.
3. Choo L.K., Malta E., Mitchelson F. Investigation of the antimuscarinic and other actions of proadifen in vitro. J. Pharm. Pharmacol. 38:1986;898-901.
4. Cole P.L., Beamer A.D., McGowan N., Cantillon C.O., Benfell K., Kelly R.A., Hartley L.H., Smith T.W., Antman E.M. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled trial of a novel antianginal agent. Circulation. 81:1990;1260-1270.
5. 2+ antagonists in the treatment of coronary disease with special reference to perhexiline maleate. In: Perhexiline Maleate. Proceedings of a Symposium. Excerpta Medica, Amsterdam, pp. 1-22.
6. Forman R., Kirk E.S. Comparative effects of vasodilator drugs on large and small coronary resistance vessels in the dog. Cardiovasc. Res. 14:1980;601-606.
7. 2+ in relation to generation of acetylcholine-induced endothelium-dependent hyperpolarization in rat mesenteric artery. Br. J. Pharmacol. 120:1997;1328-1334.
8. Garland C.J., Plane F., Kemp B.K., Cocks T.M. Endothelium-dependent hyperpolarization: a role in the control of vascular tone. T.I.P.S. 16:1995;23-30.
9. Garthwaite J., Southam E., Boulton C.L., Nielsen E.B., Schmidt K., Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol. Pharmacol. 48:1995;184-188.
10. Horowitz J.D., Sia S.T.B., MacDonald P.S., Goble A.J., Louis W.J. Perhexiline maleate treatment for severe angina pectoris- correlations with pharmacokinetics. Int. J. Cardiol. 13:1986;219-229.
11. Horowitz J.D., Button I.K., Wing L. Is perhexiline essential for the optimal management of angina pectoris? A.N.Z. J. Med. 25:1995;111-113.
12. Jeffrey F.M., Alvarez L., Diczku V., Sherry A.D., Malloy C.R. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J. Cardiovasc. Pharmacol. 25:1995;469-472.
13. Kalsner S., Nickerson M., Boyd G.N. Selective blockade of potassium-induced contractions of aortic strips by β-diethyaminoethyldiphenyl-propylacetate (SKF525A). J. Pharmacol. Exp. Ther. 174:1970;500-508.
14. Kemp B.K., Cocks T.M. Evidence that mechanisms dependent and independent of nitric oxide mediate endothelium-dependent relaxation to bradykinin in human small resistance-like coronary arteries. Br. J. Pharmacol. 120:1997;757-762.
15. Kennedy J.A., Unger S.A., Horowitz J.D. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem. Pharmacol. 52:1996;273-280.
16. Klassen G.A., Sestier F., L'Abbate A., Mildenberger R.R., Zborowska-Sluis D.T. Effects of perhexiline maleate on coronary flow distribution in the ischemic canine myocardium. Circulation. 54:1976;14-20.
17. Klaus, W., Guttler, K., 1978. Functional effects of perhexiline maleate on the isolated myocardium. In: Perhexiline Maleate. Proceedings of a Symposium. Excerpta Medica, Amsterdam, pp. 23-42.
18. Li K., Rouleau J.L., Andries L.J., Brutsaert D.L. Effect of dysfunctional vascular endothelium on myocardial performance in isolated papillary muscles. Circ. Res. 72:1993;768-777.
19. Mohan P., Brutsaert D.L., Sys S.U. Myocardial performance is modulated by interaction of cardiac endothelium derived nitric oxide and prostaglandins. Cardiovasc. Res. 29:1995;637-640.
20. Mohan P., Brutsaert D.L., Paulus W.J., Sys S.U. Myocardial contractile response to nitric oxide and cGMP. Circulation. 93:1996;1223-1229.
21. Mulvany, M.J., 1992. Procedures for investigation of small vessels using small vessel myograph. In: User Manual. JP Trading, Aarhus, Denmark.
22. Mulvany M.J., Aalkjaer C. Structure and function of small arteries. Physiol. Rev. 70:1990;921-961.
23. Newby A.C., Henderson A.H. Stimulus-secretion coupling in vascular endothelial cells. Annu. Rev. Physiol. 52:1990;661-674.
24. Parsaee H., McEwan J.R., Joseph S., MacDermot J. Differential sensitivities of the prostacyclin and nitric oxide biosynthetic pathways to cytosolic calcium in bovine aortic endothelial cells. Br. J. Pharmacol. 107:1992;1013-1019.
25. Pepine C.J., Schang J., Bemiller C.R. Effects of perhexiline on coronary hemodynamic and myocardial metabolic responses to tachycardia. Circulation. 49:1974;887-893.
26. Quilley J., Fulton D., McGiff J.C. Hyperpolarizing factors. Biochem. Pharmacol. 54:1997;1059-1070.
27. Rees J.R. Perhexiline: Good for refractory angina but take care. Int. J. Cardiol. 3:1983;157-158.
28. Stewart S., Voss D.W., Northey D.L., Horowitz J.D. Relationship bewteen plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy. Therapeutic Drug Monitoring. 18:1996;635-639.
29. Unger S.A., Robinson M.A., Horowitz J.D. Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. A.N.Z. J. Med. 27:1997;24-28.
30. Vaughan-Williams, E.M., 1980. Anti-Arrhythmic Action and the Puzzle of Perhexiline. Academic Press, London.